ArticleCell biomaterials2026
Genomic Deletion of P-Glycoprotein from Gliomas Via the Focused Ultrasound-Delivery of a Duplex CRISPR Cas9 Ribonucleoprotein System.
Article in Cell biomaterials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
P-glycoprotein (P-gp), an efflux transporter expressed in endothelium and tumor cells, restricts drug delivery to gliomas. To address this, we engineered a CRISPR Cas9 ribonucleoprotein (RNP) system that targets indels to exons 4 and 10 of the gene encoding for P-gp. Convection-enhanced delivery of this duplexed RNP system to murine gliomas inhibited efflux function in tumor cells and endothelium and improved tumor response to paclitaxel, a P-gp substrate. We then encapsulated RNPs in a lipid nanoparticle (LNP) formulation that naturally traffics to the lungs, an organ devoid of P-gp expression, and delivered them to murine gliomas with focused ultrasound (FUS). FUS-targeted LNP-RNP delivery to gliomas inhibited efflux function in tumor cells and endothelium and enhanced paclitaxel therapy. Our results conceptually illustrate a strategy wherein LNP-encapsulated CRISPR Cas9 cargo in the bloodstream is targeted to the brain with FUS, while off-target LNPs are biochemically trafficked to an innocuous sink organ.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.